NeuroPace (NPCE) Projected to Release Quarterly Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect NeuroPace to announce earnings of ($0.0862) per share and revenue of $27.13 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The company had revenue of $22.83 million for the quarter, compared to the consensus estimate of $22.61 million. On average, analysts expect NeuroPace to post ($0.67) EPS for the current fiscal year and ($0.21) EPS for the next fiscal year.

NeuroPace Trading Up 0.6%

NASDAQ:NPCE opened at $12.99 on Tuesday. NeuroPace has a 12 month low of $9.22 and a 12 month high of $19.60. The firm has a market cap of $445.82 million, a price-to-earnings ratio of -22.79 and a beta of 1.86. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The company’s 50 day moving average is $13.80 and its 200-day moving average is $15.06.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on NPCE shares. KeyCorp began coverage on shares of NeuroPace in a report on Thursday, September 17th. They set an “overweight” rating and a $18.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of NeuroPace in a research report on Wednesday, July 29th. Raymond James Financial set a $21.00 price target on shares of NeuroPace in a report on Tuesday, September 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th. Finally, Mizuho assumed coverage on NeuroPace in a research report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.33.

About NeuroPace

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. Its principal product is the RNS System, an implantable responsive neurostimulation device designed to detect abnormal electrical activity in the brain and deliver targeted stimulation intended to prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed at or near seizure-onset areas, and a programming and data-management platform used by healthcare professionals.